You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 149 No. 3, March 1989 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL INVESTIGATIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Treatment of Recurrent Thyroid Cysts by Injection of Tetracycline or Minocycline

Jenn-Kuen Lee, MD; Fang-Ting Tai, MD; Hong-Da Lin, MD; Yi-Hong Chou, MD; Michael M. Kaplan, MD; King-Nien Ching, MD

Arch Intern Med. 1989;149(3):599-601.


Abstract

• We analyzed the effects of tetracycline hydrochloride or minocycline hydrochloride sclerotherapy on 66 recurrent thyroid cysts. All were hemorrhagic lesions except one serous cyst; cytologic study showed all were benign. On average, three treatments were given until resolution or the patient became unavailable for follow-up. The cumulative frequency of cyst disappearance was 33%, 45%, 52%, and 59% after 1, 2, 3, and 4 treatments. Five additional patients had cyst resolution after six to 19 treatments, and the serous lesion did not resolve. Cysts requiring more than two treatments were larger at presentation than those resolving after one or two treatments. Side effects in 179 treatments were local pain lasting ten to 20 minutes in 4.5%, radiated pain lasting one to two hours in 4.5%, fatigue lasting one to two days in 3.9%, and a febrile sensation lasting one to two days in 2.8%. Hemorrhagic thyroid cysts can usually be cured by repeated tetracycline or minocycline sclerotherapy with tolerable side effects.

(Arch Intern Med 1989;149:599-601)



Author Affiliations

From the Division of Endocrinology and Metabolism, Department of Medicine (Drs Lee, Tai, Lin, and Ching), and Department of Radiology (Dr Chou), Veterans General Hospital and National Yang-Ming Medical College, Taipei, Taiwan, Republic of China; and New England Medical Center, Boston (Drs Lee and Kaplan). Dr Lee is now with the Thyroid Unit, Massachusetts General Hospital, Boston, and Dr Kaplan is now with Farmbrook Medical Two, Southfield, Mich.


Footnotes

Accepted for publication Aug 13, 1988.

Reprint requests to Thyroid Unit, Massachusetts General Hospital, Boston, MA 02114 (Dr Lee).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Management of Simple Nodular Goiter: Current Status and Future Perspectives
Hegedus et al.
Endocr. Rev. 2003;24:102-132.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1989 American Medical Association. All Rights Reserved.